Oral antidiabetic drugs for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

COVID-OUT (metformin), 2022 NCT04510194

metformin (n=663) vs. placebo (n=660)

randomized controlled trial

Studied treatment

immediate-release metformin administered with an increase in dose over 6 days to 1500 mg per day for 14 days,

Control treatment

placebo

Patients

COVID 19 outpatients

Method

double-blind

US, 6 centres

2-by-3 factorial design (metformin, ivermectin, and fluvoxamine)

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open